Carvestad 12.5

Carvedilol is a nonselective β-adrenergic blocking agent with selective α1– adrenergic blocking activity. Vasodilation resulting in reduced total peripheral resistance mediated through carvedilol’s α1-adrenergic blockade and reduced sympathetic tone appears to play a major role in the drug’s hypotensive effect.

Pack size Box of 30 tablets, 100 tablets Bottle of 30 tablets
Shelf-life 36 months
Composition Carvedilol
Dosage forms and strengths Tablet: 12.5 mg
Product code :



  • Hypertension.
  • Angina pectoris.
  • Heart failure.
  • Left ventricular dysfunction following myocardial infarction.


  • Hypertension:
    Initial dose of 12.5 mg once daily, increased after two days to 25 mg once daily. Alternatively, an initial dose of 6.25 mg twice daily, increased after one to two weeks to 12.5 mg twice daily. The dose may be increased further, if necessary, at intervals of at least 2 weeks, to 50 mg once daily or in divided doses. Elderly: 12.5 mg once daily.
  • Angina pectoris:
    Initial dose of 12.5 mg is given twice daily, increased after two days to 25 mg twice daily.
  •  Heart failure:
    Initial dose is 3.125 mg twice daily, taken with food to reduce the risk of hypotension. If tolerated, the dose should be doubled after two weeks to 6.25 mg twice daily and then increased gradually, at intervals of not less than 2 weeks, to the maximum dose tolerated; should not exceed 25 mg twice daily (severe heart failure or < 85 kg) or 50 mg twice daily (mild to moderate heart failure and > 85 kg).
  • Left ventricular dysfunction following myocardial infarction:
    Initial dose is 6.25 mg twice daily, increased after 3 to 10 days, if tolerated, to 12.5 mg twice daily and then to a target dose of 25 mg twice daily. A lower initial dose may be used in symptomatic patients.


  • Carvestad 12.5 is administered orally.
  • Known hypersensitivity to any of the ingredients.
  • Bronchial asthma or related bronchospastic conditions.
  • Second or third degree AV block.
  • Sick sinus syndrome or severe bradycardia (unless a permanent pacemaker is in place).
  • Cardiogenic shock.
  • Decompensated heart failure requiring the use of intravenous inotropic therapy.
  • Hepatic impairment.


  • Headache, muscle pain, fatigue, dyspnea;
  • Vertigo, postural hypotension;
  • Nausea.
  • Patients with congestive heart failure treated with digitalis, diuretics, or ACE-inhibitors.
  • Uncontrolled or difficult to control diabetes.
  • Peripheral vascular disease.
  • Undergoing anesthesia.
  • Hyperthyroidism
  • Bronchospastic disease (very small doses may be used if no other antihypertensive is tolerated).
  • Consider if concurrently use with inhalation anaesthetics or combined with class-I-antiarrhythmic drugs.
  • Discontinued if any evidence of liver injury occurs.
  • Abrupt withdrawal of the drug should be avoided.
  • The safety and efficacy of carvedilol in children have not been established.
  • During pregnancy: should only use if the potential benefit justifies the risk, and not during the third trimester or in connection with partus.
  • Should not use in patients with rare hereditary problems of galactose or fructose intolerance, total lactase or sucrase-isomaltase deficiency or glucose-galactose malabsorption.
  • Patients should be aware of how they react to drug before driving or operating machinery.